UNSPSC 51351523: Hydroxyprogesterone acetate

This classification denotes a therapeutic progestin C23H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L124O66YSI, chemically known as 17.alpha.-hydroxy-4-pregnene-3,20-dione acetate, but more generally known as hydroxyprogesterone acetate, which bears US NIH Compound Identifier 9325. European Medicines Agency schedules Hydroxyprogesterone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16436MIG.

Most nations, for tariff and trade purposes, schedule hydroxyprogesterone acetate under HS 29372300 and SITC 54153. As of Q4 2014, HYDROXYPROGESTERONE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)OC(=O)C.

UNSPSC 51351523 Hydroxyprogesterone acetate is a Commodity code covering specific pharmaceutical active ingredients procured through multistate cooperative purchasing vehicles to supply state and local government healthcare facilities. State and local governments buy this product as part of broader pharmaceutical procurement frameworks rather than as standalone line items, typically through generic-sourcing agreements that consolidate purchasing across multiple jurisdictions and authorized wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body active in this space, establishing contracts that serve participating state agencies, local government health systems, and facilities across multiple states including Oregon. Vendors supplying hydroxyprogesterone acetate and related active pharmaceutical ingredients under this code must meet stringent regulatory requirements, including FDA compliance, current Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) compliance; maintain contractual relationships with multiple authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC) with functioning chargeback systems; and provide detailed product specifications including National Drug Codes (NDC), UPCs, and manufacturing locations. Pricing models accepted include fixed price, net price formats, and WAC-minus structures, with vendors typically absorbing a 3 percent administrative fee on contract purchases.

MMCAP's January 2026 RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, represents the most active recent procurement vehicle in this code. The evaluation weighted price competitiveness at 75 percent of the overall score, with remaining points allocated to fixed pricing, administrative compliance, EDI capability, and fee agreement. Awarded vendors must maintain comprehensive insurance coverage including $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability. Contract awards become effective July 1, 2026, for new responders on a two-year term with optional extensions at MMCAP's discretion, while incumbent vendor amendments extend through June 30, 2028. The RFP does not disclose specific budget ranges or set-aside restrictions; performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. Questions close on February 18, 2026.